TrialNature communications2023

Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults.

Karina A Pasquevich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.